Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by USS Investment Management Ltd

USS Investment Management Ltd grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 45,393 shares of the pharmaceutical company’s stock after purchasing an additional 1,294 shares during the period. USS Investment Management Ltd’s holdings in Vertex Pharmaceuticals were worth $20,584,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of VRTX. Brighton Jones LLC boosted its stake in Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares in the last quarter. Gamco Investors INC. ET AL bought a new position in Vertex Pharmaceuticals during the second quarter valued at about $228,000. NewEdge Advisors LLC boosted its stake in Vertex Pharmaceuticals by 9.0% during the second quarter. NewEdge Advisors LLC now owns 11,929 shares of the pharmaceutical company’s stock valued at $5,311,000 after buying an additional 986 shares in the last quarter. ICW Investment Advisors LLC boosted its stake in Vertex Pharmaceuticals by 5.0% during the second quarter. ICW Investment Advisors LLC now owns 604 shares of the pharmaceutical company’s stock valued at $269,000 after buying an additional 29 shares in the last quarter. Finally, Diversify Advisory Services LLC boosted its stake in Vertex Pharmaceuticals by 26.3% during the second quarter. Diversify Advisory Services LLC now owns 7,291 shares of the pharmaceutical company’s stock valued at $3,246,000 after buying an additional 1,518 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on VRTX shares. Morgan Stanley raised their target price on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a research note on Tuesday, May 5th. Truist Financial started coverage on Vertex Pharmaceuticals in a research note on Wednesday, May 27th. They set a “buy” rating and a $542.00 target price for the company. Canaccord Genuity Group decreased their target price on Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a research note on Tuesday, May 5th. Barclays raised their target price on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Royal Bank Of Canada raised their target price on Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Twenty-two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $555.91.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $444.92 on Monday. The company has a 50 day simple moving average of $437.14 and a 200-day simple moving average of $452.53. The firm has a market capitalization of $112.92 billion, a price-to-earnings ratio of 26.39, a price-to-earnings-growth ratio of 1.90 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.23. The business had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The firm’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the company earned $4.06 EPS. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current year.

Insider Activity

In other news, Director Sangeeta N. Bhatia sold 318 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the sale, the director directly owned 4,924 shares in the company, valued at $2,086,446.52. The trade was a 6.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 1,745 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $450.00, for a total value of $785,250.00. Following the sale, the chief marketing officer owned 21,015 shares of the company’s stock, valued at approximately $9,456,750. This represents a 7.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,133 shares of company stock worth $4,973,106 in the last three months. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received bullish attention from market commentary highlighting that Wall Street remains interested in the stock despite a bearish “death cross” technical setup, suggesting investors are focusing more on the company’s fundamentals than the chart pattern. Article Title
• Positive Sentiment: The company announced new CASGEVY data at the European Hematology Association Congress, including the first European presentation of results in children ages 5–11 and additional global regulatory submissions, which could support longer-term growth for the gene-editing therapy. Article Title
• Positive Sentiment: Analysts and media coverage have been broadly upbeat on Vertex, including pieces describing it as a favored healthcare stock and a stock some investors view as attractive to buy now, reinforcing confidence in the name. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small revision that may not materially change the long-term outlook but is a minor headwind for sentiment. Article Title
• Negative Sentiment: The stock has also experienced a recent pullback in some sessions, reflecting normal volatility and some profit-taking even as the broader narrative remains constructive. Article Title

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.